The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study

Virology Journal

Volumn 4, Issue , 2007, Pages

  De La Cruz Hernández, Erick ^a   Pérez Cárdenas, Enrique ^b   Contreras Paredes, Adriana ^a   Cantú, David ^b   Mohar, Alejandro ^a   Lizano, Marcela ^a   Dueñas González, Alfonso ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; LYSINE; PROTEIN BAX; PROTEIN E6; PROTEIN E7; PROTEIN P53; VALPROIC ACID;

ACETYLATION; AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; TRANSACTIVATION; TRANSCRIPTION REGULATION; UPREGULATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS GENE; WART VIRUS;

ACETYLATION; ALPHAPAPILLOMAVIRUS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA METHYLATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, VIRAL; GENES, P53; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDRALAZINE; ONCOGENE PROTEINS, VIRAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

HUMAN PAPILLOMAVIRUS;

EID: 33847772150     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-4-18     Document Type: Article

References (49)

1. Global cancer statistics, 2002. DM Parkin F Bray J Ferlay P Pisani, CA Cancer J Clin 2005 55 74 108 15761078
2. Viral genes and methylation. M Verma, Ann N Y Acad Sci 2003 983 170 180 12724222
3. Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Q Tao H Huang TM Geiman CY Lim L Fu GH Qiu KD Robertson, Hum Mol Genet 2002 11 2091 2102 10.1093/hmg/11.18.2091 12189161
4. Stealth technology: how Epstein-Barr virus utilizes DNA methylation to cloak itself from immune detection. Q Tao KD Robertson, Clin Immunol 2003 109 53 63 10.1016/S1521-6616(03)00198-0 14585276
5. Viral oncoproteins target the DNA methyltransferases. WA Burgers L Blanchon S Pradhan YD Launoit T Kouzarides F Fuks, Oncogene 2006 Sep 18 16983344
6. The effect of DNA methylation on gene regulation of human papillomaviruses. F Rosl A Arab B Klevenz H zur Hausen, J Gen Virol 1993 74 791 801 8388016
7. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. V Badal LS Chuang EH Tan S Badal LL Villa CM Wheeler BF Li HU Bernard, Virology 2003 77 6227 6234 10.1128/JVI.77.11.6227-6234.2003
8. The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. S Badal V Badal IE Calleja-Macías M Kalantari LS Chuang BF Li HU Bernard, Virology 2004 324 483 492 10.1016/j.virol.2004.04.002 15207633
9. CpG methylation directly inhibits binding of the human papillomavirus type 16 E2 protein to specific DNA sequences. A Thain O Jenkins AR Clarke K Gaston, J Virol 1996 70 7233 7235 8794373
10. Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. K Kim PA Garner-Hamrick C Fisher D Lee PF Lambert, J Virol 2003 77 12450 12459 14610169 10.1128/JVI.77.23.12450-12459.2003
11. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. WG Zhu GA Otterson, Curr Med Chem Anti-Cancer Agents 2003 3 187 199 10.2174/ 1568011033482440
12. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. EE Cameron KE Bachman S Myohanen JG Herman SB Baylin, Nat Genet 1999 21 103 107 10.1038/5047 9916800
13. Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. L Li H Shi C Yiannoutsos TH Huang KP Nephew, J Comput Biol 2005 12 370 390 10.1089/cmb.2005.12.370 15857248
14. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. M Primeau J Gagnon RL Momparler, Int J Cancer 2003 103 177 184 10.1002/ijc.10789 12455031
15. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. WG Zhu RR Lakshmanan MD Beal GA Otterson, Cancer Res 2001 61 1327 1333 11245429
16. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. MI Klisovic EA Maghraby MR Parthun M Guimond AR Sklenar, Leukemia 2003 17 350 358 10.1038/sj.leu.2402776 12592335
17. Interaction of 5-aza-2'-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. J Gagnon S Shaker M Primeau A Hurtubise RL Momparler, Anticancer Drugs 2003 14 193 202 10.1097/00001813-200303000-00002 12634613
18. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. V Bovenzi RL Momparler, Cancer Chemother Pharmacol 2001 48 71 76 10.1007/s002800100294 11488527
19. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. B Segura-Pacheco C Trejo-Becerril E Pérez-Cárdenas L Taja-Chayeb I Mariscal A Chávez C Acũa AM Salazar M Lizano A Duẽas- González, Clin Cancer Res 2003 9 1596 1603 12738711
20. Computational studies of 1-Hydrazinophtalazine (Hydralazine) as antineoplastic agent. Docking studies on methyltransferase. E Angeles VH Vázquez-Valadez O Vázquez-Valadez AM Velázquez- Sánchez A Ramírez L Martínez S Díaz-Barriga A Romero-Rojas G Cabrera R López-Castãares A Duẽas- González, Lett Drug Design Discov 2005 4 282 286 10.2174/1570180054038413
21. Hydralazine target: from blood vessels to the epigenome. C Arce B Segura-Pacheco E Perez-Cardenas L Taja-Chayeb M Candelaria A Duennas-Gonzalez, J Transl Med 2006 4 10 16507100 10.1186/1479-5876-4-10
22. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. P Zambrano B Segura-Pacheco E Perez-Cardenas L Cetina A Revilla-Vazquez L Taja-Chayeb A Chavez-Blanco E Angeles G Cabrera K Sandoval C Trejo-Becerril J Chanona-Vilchis A Duenas-Gonzalez, BMC Cancer 2005 5 44 15862127 10.1186/1471-2407-5-44
23. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. A Chavez-Blanco C Perez-Plasencia E Perez-Cardenas C Carrasco-Legleu E Rangel-Lopez B Segura-Pacheco L Taja-Chayeb C Trejo-Becerril A Gonzalez-Fierro M Candelaria G Cabrera A Duenas-Gonzalez, Cancer Cell Int 2006 6 2 16448574 10.1186/1475-2867-6-2
24. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. A Chávez-Blanco B Segura-Pacheco E Pérez- Cárdenas L Taja-Chayeb L Cetina M Candelaria D Cantu C Perez-Plasencia G Cabrera C Trejo-Becerril E Angeles A Gonzalez-Fierro P García-Lopez P Zambrano A Duenas-Gonzalez, Mol Cancer 2005 4 22 16001982 10.1186/1476-4598-4-22
25. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. C Arce C Perez-Plasencia A Gonzalez-Fierro E de la Cruz-Hernandez A Revilla-Vazquez A Chavez-Blanco C Trejo-Becerril E Perez-Cardenas L Taja-Chayeb E Bargallo P Villarreal T Ramirez T Vela M Candelaria MF Camargo E Robles A Duenas-Gonzalez, PLoS ONE 2006 1 e98 17183730 10.1371/journal.pone.0000098
26. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases. L Huang, J Cell Physiol 2006 209 611 616 10.1002/jcp.20781 17001696
27. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. QC Ryan D Headlee M Acharya A Sparreboom JB Trepel J Ye WD Figg K Hwang EJ Chung A Murgo G Melillo Y Elsayed M Monga M Kalnitskiy J Zwiebel EA Sausville, J Clin Oncol 2005 23 3912 3922 10.1200/JCO.2005.02.188 15851766
28. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. P Maslak S Chanel LH Camacho S Soignet PP Pandolfi I Guernah R Warrell S Nimer, Leukemia 2006 20 212 217 10.1038/sj.leu.2404050 16357841
29. Phase I/II study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. G García-Manero HM Kantarjian B Sánchez-González H Yang G Rosner S Verstovsek M Rytting WG Wierda F Ravandi C Koller L Xiao S Faderl Z Estrov J Cortes S O'brien E Estey C Bueso-Ramos J Fiorentino E Jabbour JP Issa, Blood 2006 108 3271 3279 10.1182/blood-2006-03-009142 16882711
30. Epigenetics of cervical cancer. An overview and therapeutic perspectives. A Duenas-Gonzalez M Lizano M Candelaria L Cetina C Arce E Cervera, Mol Cancer 2005 4 38 16248899 10.1186/1476-4598-4-38
31. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. HJ Yang VW Liu Y Wang PC Tsang HY Ngan, BMC Cancer 2006 6 212 16928264 10.1186/1471-2407-6-212
32. Interplay of viral and cellular proteins along the long control region of human papillomavirus type 18. A Garcia-Carranca F Thierry M Yaniv, J Virol 1988 62 4321 4330 2845145
33. Clusters of nuclear factor I binding sites identify enhancers of several papillomaviruses but alone are not sufficient for enhancer function. B Gloss M Yeo-Gloss M Meisterenst L Rogge EL Winnacker HU Bernard, Nucleic Acids Res 1989 17 3519 3533 2542901 10.1093/nar/17.9.3519
34. Transcriptional control of human papillomavirus (HPV) oncogene expression: composition of the HPV type 18 upstream regulatory region. K Butz F Hoppe-Seyler, J Virol 1993 67 6476 6486 8411351
35. Clonal selection for transcriptionally active viral oncogenes during progression to cancer. BA Van Tine JC Kappes NS Banerjee J Knops L Lai RD Steenbergen CL Meijer PJ Snijders P Chatis TR Broker PT Moen Jr LT Chow, J Virol 2004 78 11172 11186 15452237 10.1128/JVI.78.20.11172-11186.2004
36. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer. K Hamada T Shirakawa A Gotoh JA Roth M Follen, Gynecol Oncol 2006 103 820 830 10.1016/j.ygyno.2006.06.035 16908054
37. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. K Hamada M Sakaue R Alemany WW Zhang Y Horio JA Roth MF Mitchell, Gynecol Oncol 1996 63 219 227 10.1006/gyno.1996.0310 8910631
38. In vitro and in vivo inhibition of human papillomavirus type 16 E6 and E7 genes. TM Tan RC Ting, Cancer Res 1995 55 4599 4605 7553636
39. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. EC Goodwin D DiMaio, Proc Natl Acad Sci USA 2000 97 12513 12518 11070078 10.1073/pnas.97.23.12513
40. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. X Agirre J Roman-Gomez A Jimenez-Velasco L Garate C Montiel-Duarte G Navarro I Vazquez M Zalacain MJ Calasanz A Heiniger A Torres JD Minna F Prosper, Oncogene 2006 25 1862 1870 10.1038/sj.onc.1209236 16314841
41. High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. TA Sohn R Bansal GH Su KM Murphy SE Kern, Carcinogenesis 2002 23 949 957 10.1093/carcin/23.6.949 12082016
42. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. MV Blagosklonny S Trostel G Kayastha ZN Demidenko LT Vassilev LY Romanova S Bates T Fojo, Cancer Res 2005 65 7386 7392 10.1158/0008-5472.CAN-04- 3433 16103091
43. The histone deacetylase inhibitor FR901228 (desipeptide) restores expression and function of pseudo-null p53. M Kitazono S Bates P Fok T Fojo MV Blagosklonny, Cancer Biol Ther 2002 2 665 668
44. Reactivation of mutant p53: a new strategy for cancer therapy. G Selivanova T Kawasaki L Ryabchenko KG Wiman, Semin Cancer Biol 1998 8 369 378 10.1006/scbi.1998.0099 10101802
45. Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Y Zhao S Lu L Wu G Chai H Wang Y Chen J Sun Y Yu W Zhou Q Zheng M Wu GA Otterson WG Zhu, Mol Cell Biol 2006 26 2782 2790 16537920 10.1128/MCB.26.7.2782-2790.2006
46. Site specific acetylation of p53 directs selective transcription complex assembly. S Roy M Tenniswood, J Biol Chem 2007 282 4765 4771 10.1074/jbc.M609588200 17121856
47. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. M Scheffner JM Huibregtse PM Howley, Proc Natl Acad Sci USA 1994 91 8797 8801 8090726 10.1073/pnas.91.19.8797
48. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. M Scheffner JM Huibregtse RD Vierstra PM Howley, Cell 1993 75 495 505 10.1016/0092-8674(93)90384-3 8221889
49. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. T Miyashita JC Reed, Cell 1995 80 293 299 10.1016/0092-8674(95)90513-8 7834749